Phathom Pharmaceuticals to present at investor conferences in September.
ByAinvest
Monday, Aug 25, 2025 8:03 am ET1min read
PHAT--
At the Cantor Global Healthcare Conference 2025, scheduled for September 3-5, Phathom's management team will participate in one-on-one meetings throughout the conference. The live webcast of the event will be available on the Phathom website. For those unable to attend, the webcast will be archived for up to 90 days following the conclusion of the event [1].
The H.C. Wainwright 27th Annual Global Investment Conference, taking place from September 8-10, will also feature Phathom's management team, who will participate in one-on-one meetings. The live webcast of this event will be available on the Phathom website as well. The webcast will be archived for up to 90 days following the conclusion of the event [1].
Phathom Pharmaceuticals focuses on developing and commercializing novel treatments for gastrointestinal diseases. The company markets VOQUEZNA®, a first-in-class potassium-competitive acid blocker (PCAB) for various gastrointestinal conditions including Non-Erosive GERD and H. pylori infection treatment [1].
References:
[1] https://www.stocktitan.net/news/PHAT/phathom-pharmaceuticals-to-participate-in-upcoming-investor-nnibl7okihup.html
Phathom Pharmaceuticals has announced that management team members will participate in investor conferences in September. The events include the Cantor Global Healthcare Conference 2025 in New York from September 3-5 and the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10. The conferences will feature 1x1 meetings and live webcasts, accessible on the Phathom website.
Phathom Pharmaceuticals (NASDAQ: PHAT) has announced that its management team will participate in two upcoming investor conferences in September 2025. The events include the Cantor Global Healthcare Conference 2025 in New York from September 3-5 and the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10. Both conferences will feature one-on-one meetings and live webcasts, accessible on the Phathom website.At the Cantor Global Healthcare Conference 2025, scheduled for September 3-5, Phathom's management team will participate in one-on-one meetings throughout the conference. The live webcast of the event will be available on the Phathom website. For those unable to attend, the webcast will be archived for up to 90 days following the conclusion of the event [1].
The H.C. Wainwright 27th Annual Global Investment Conference, taking place from September 8-10, will also feature Phathom's management team, who will participate in one-on-one meetings. The live webcast of this event will be available on the Phathom website as well. The webcast will be archived for up to 90 days following the conclusion of the event [1].
Phathom Pharmaceuticals focuses on developing and commercializing novel treatments for gastrointestinal diseases. The company markets VOQUEZNA®, a first-in-class potassium-competitive acid blocker (PCAB) for various gastrointestinal conditions including Non-Erosive GERD and H. pylori infection treatment [1].
References:
[1] https://www.stocktitan.net/news/PHAT/phathom-pharmaceuticals-to-participate-in-upcoming-investor-nnibl7okihup.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet